Vogenx prices $81.25 million IPO ahead of Nasdaq listing under VOGX

Vogenx, Inc., a clinical-stage biopharmaceutical company, filed a prospectus dated August 11, 2026 for an initial public offering of 6,250,000 shares of common stock. The initial public offering price is $13.00 per share.¹

At that price, the offering is expected to generate $81,250,000 in gross proceeds, with $75,562,500 in proceeds before expenses to the company after underwriting discounts and commissions.¹ The company has granted underwriters a 45-day option to purchase up to 937,500 additional shares at the IPO price, less discounts and commissions.¹ Underwriters expect to deliver the shares against payment in New York on August 13, 2026.¹

The common stock has been approved for listing on the Nasdaq Capital Market under the symbol "VOGX."¹ The prospectus does not confirm that trading has actually commenced as of its filing date; delivery of shares is expected two days after the prospectus date.

The company's lead candidate is mizagliflozin, described as an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS¹. The company has begun study startup activities for its Phase 2b EMERGE study for the PBH program and expects to begin screening patients in 2026.¹

On financials, the company's net loss was $2.2 million and $1.4 million for the years ended December 31, 2024 and 2025, respectively, and $475 thousand for the three months ended March 31, 2026.¹ As of March 31, 2026, the accumulated deficit stood at $11.3 million.¹ Net proceeds from the offering are estimated at approximately $73.6 million, intended to fund continued development of mizagliflozin along with other corporate purposes.¹